These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 17982334)

  • 1. The transdermal contraceptive patch: an updated review of the literature.
    O'Connell K; Burkman RT
    Clin Obstet Gynecol; 2007 Dec; 50(4):918-26. PubMed ID: 17982334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transdermal contraceptive patch: a new approach to hormonal contraception.
    Burkman RT
    Int J Fertil Womens Med; 2002; 47(2):69-76. PubMed ID: 11991433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethinylestradiol + norelgestromin: new preparation. Transdermal contraception: no tangible progress.
    Prescrire Int; 2004 Aug; 13(72):123-6. PubMed ID: 15532134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical study of transdermal contraceptive patch in Thai adolescence women.
    Piyasirisilp R; Taneepanichskul S
    J Med Assoc Thai; 2008 Feb; 91(2):137-41. PubMed ID: 18389975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Brenner P
    Contraception; 2006 Oct; 74(4):354; author reply 354-5. PubMed ID: 16982246
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile.
    Creasy GW; Fisher AC; Hall N; Shangold GA
    J Reprod Med; 2003 Mar; 48(3):179-86. PubMed ID: 12698776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
    Cole JA; Norman H; Doherty M; Walker AM
    Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transdermal contraceptive system.
    Burkman RT
    Am J Obstet Gynecol; 2004 Apr; 190(4 Suppl):S49-53. PubMed ID: 15105798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cycle control and side effects between transdermal contraceptive patch and an oral contraceptive in women older than 35 years.
    Boonyarangkul A; Taneepanichskul S
    J Med Assoc Thai; 2007 Sep; 90(9):1715-9. PubMed ID: 17957909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy.
    Archer DF; Cullins V; Creasy GW; Fisher AC
    Contraception; 2004 Mar; 69(3):189-95. PubMed ID: 14969665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.
    Devineni D; Skee D; Vaccaro N; Massarella J; Janssens L; LaGuardia KD; Leung AT
    J Clin Pharmacol; 2007 Apr; 47(4):497-509. PubMed ID: 17389559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oral versus transdermal steroidal contraceptives on androgenic markers.
    White T; Jain JK; Stanczyk FZ
    Am J Obstet Gynecol; 2005 Jun; 192(6):2055-9. PubMed ID: 15970897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS; Jick H
    Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal hormonal contraception: benefits and risks.
    Burkman RT
    Am J Obstet Gynecol; 2007 Aug; 197(2):134.e1-6. PubMed ID: 17689623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra.
    Harel Z; Riggs S; Vaz R; Flanagan P; Dunn K; Harel D
    J Pediatr Adolesc Gynecol; 2005 Apr; 18(2):85-90. PubMed ID: 15897103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined hormonal contraception and venous thromboembolism.
    Martínez F; Avecilla A
    Eur J Contracept Reprod Health Care; 2007 Jun; 12(2):97-106. PubMed ID: 17559006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study.
    Fleischer K; van Vliet HA; Rosendaal FR; Rosing J; Tchaikovski S; Helmerhorst FM
    Thromb Res; 2009; 123(3):429-35. PubMed ID: 18829069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.